

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

959 Selected Articles from This Issue

REVIEW

961 **Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?**
Robert W. Lentz, Meryl D. Colton, Siddhartha S. Mitra, and Wells A. Messersmith

SMALL MOLECULE THERAPEUTICS

975 **The KRAS^{G12C} Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy**
David M. Briere, Shuai Li, Andrew Calinisan, Niranjana Sudhakar, Ruth Aranda, Lauren Hargis, David H. Peng, Jiehui Deng, Lars D. Engstrom, Jill Hallin, Sole Gatto, Julio Fernandez-Banet, Adam Pavlicek, Kwok-Kin Wong, James G. Christensen, and Peter Olson

986 **Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of *NF2*-deficient Mesothelioma**
Tracy T. Tang, Andrei W. Konradi, Ying Feng, Xiao Peng, Mingyue Ma, Jian Li, Fa-Xing Yu, Kun-Liang Guan, and Leonard Post

999 **Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers**
Ahmed Hamed Salem, Zhi-Fu Tao, Orlando F. Bueno, Jie Chen, Shuang Chen, Rohinton Edalji, Steven W. Elmore, Keith M. Fournier, Kaid C. Harper, Richard Hong, Gary J. Jenkins, Jianguo Ji, Russell A. Judge, John C. Kalvass, Russell C. Klix, Yi-Yin Ku, Joel D. Levenson, Richard A. Marks, Kennan C. Marsh, Rajeev M. Menon, Chang H. Park, Darren C. Phillips, Yu-Ming Pu, Saul H. Rosenberg, Yeshwant D. Sanzgiri, Ahmad Y. Sheikh, Yi Shi, Deanne Stolarik, Ahmed A. Suleiman, Xilu Wang, Geoff G.Z. Zhang, Nathaniel D. Catron, and Andrew J. Souers

1009 ***In Vivo* Efficacy of Tesevatinib in *EGFR*-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling**

Sani H. Kizilbash, Shiv K. Gupta, Karen E. Parrish, Janice K. Laramy, Minjee Kim, Gautham Gampa, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, William F. Elmquist, and Jann N. Sarkaria

1019 **Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein-coupled Receptor 68**

Takahiro Yamanaka, Norifumi Harimoto, Takehiko Yokobori, Ryo Muranushi, Kouki Hoshino, Kei Hagiwara, Dolgormaa Gantumur, Tadashi Handa, Norihiro Ishii, Mariko Tsukagoshi, Takamichi Igarashi, Akira Watanabe, Norio Kubo, Kenichiro Araki, Kazuo Umezawa, and Ken Shirabe

1029 **Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma**

Miguel Jiménez-Alcázar, Álvaro Curiel-García, Paula Nogales, Javier Perales-Patón, Alberto J. Schuhmacher, Marcos Galán-Ganga, Lucía Zhu, Scott W. Lowe, Fátima Al-Shahrour, and Massimo Squatrito

1039 **Enhancing Proteotoxic Stress in Leiomyosarcoma Cells Triggers Mitochondrial Dysfunctions, Cell Death, and Antitumor Activity *in vivo***

Luca Iuliano, Sara Drioli, Ymera Pignochino, Claudia Maria Cafiero, Martina Minisini, Francesca D’Este, Raffaella Picco, Emiliano Dalla, Giorgia Giordano, Giovanni Grignani, Eros Di Giorgio, Fabio Benedetti, Fulvia Felluga, and Claudio Brancolini

1052 **Hormone-Dependent Prostate Cancers are Dependent on Rac Signaling for Growth and Survival**

Erik T. Goka, Dayrelis T. Mesa Lopez, and Marc E. Lippman

TABLE OF CONTENTS

1062 Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer

Jessica L. Christenson, Kathleen I. O'Neill, Michelle M. Williams, Nicole S. Spoelstra, Kenneth L. Jones, G. Devon Trahan, Jordan Reese, Elaina T. Van Patten, Anthony Elias, Joel R. Eisner, and Jennifer K. Richer

1072 BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes

Mina Nikanjam, Jose Tinajero, Donald A. Barkauskas, and Razelle Kurzrock

1080 Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3K γ Inhibition

Larissa S. Carnevali, Molly A. Taylor, Matthew King, Anna M.L. Coenen-Stass, Adina M. Hughes, Sigourney Bell, Theresa A. Proia, Yanjun Wang, Antonio Ramos-Montoya, Neha Wali, Danielle Carroll, Maneesh Singh, Michele Moschetta, Pablo Morentin Gutierrez, Cristina Gardelli, Susan E. Critchlow, Teresa Klinowska, Stephen E. Fawell, and Simon T. Barry

1092 Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation

Weini Wang, Fang Fang, Ali Ozes, and Kenneth P. Nephew

LARGE MOLECULE THERAPEUTICS

1102 Novel TGF β Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy

Nils Ludwig, Lukasz Wieteska, Cynthia S. Hinck, Saigopalakrishna S. Yerneni, Juliana H. Azambuja, Richard J. Bauer, Torsten E. Reichert, Andrew P. Hinck, and Theresa L. Whiteside

1112 Calicheamicin Antibody-Drug Conjugates with Improved Properties

Breanna S. Vollmar, Chris Frantz, Melissa M. Schutten, Fiona Zhong, Geoffrey del Rosario, Mary Ann T. Go, Shang-Fan Yu, Douglas D. Leipold, Amrita V. Kamath, Carl Ng, Keyang Xu, Josefa dela Cruz-Chuh, Katherine R. Kozak, Jinhua Chen, Zijin Xu, John Wai, Pragma Adhikari, Hans K. Erickson, Peter S. Dragovich, Andrew G. Polson, and Thomas H. Pillow

1121 Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate

Ming-Chen Yang, Chi-Sheng Shia, Wan-Fen Li, Chun-Chung Wang, I-Ju Chen, Teng-Yi Huang, Yu-Jung Chen, Hui-Wen Chang, Chi-Huan Lu, Yueh-Chin Wu, Nan-Hsuan Wang, Jiann-Shiun Lai, Cheng-Der Yu, and Ming-Tain Lai

1133 Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

A C Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki, Shigeki Yoshiura, Naoki Harada, and Yasushi Yoshimura

1142 A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization

Mirim Hong, Youngki Yoo, Miyoung Kim, Ju Yeon Kim, Jeong Seok Cha, Myung Kyung Choi, Uijin Kim, Kyungyong Kim, Youngsoo Sohn, Donggoo Bae, Hyun-Soo Cho, and Seung-Beom Hong

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1153 RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC

Hiroyuki Arai, Shu Cao, Francesca Battaglin, Jingyuan Wang, Natsuko Kawanishi, Ryuma Tokunaga, Fotios Loupakis, Sebastian Stintzing, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M. Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, and Heinz-Josef Lenz

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

1161 High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

A C Lindy Vernooij, Laurel T. Bate-Eya, Lindy K. Alles, Jasmine Y. Lee, Bianca Koopmans, Hunter C. Jonus, Nil A. Schubert, Linda Schild, Daphne Lelieveld, David A. Egan, Mark Kerstjens, Ronald W. Stam, Jan Koster, Kelly C. Goldsmith, Jan J. Molenaar, and M. Emmy M. Dolman

1173 ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib

Wenlong Li, Rolf W. Sparidans, Margarida L.F. Martins, Mujtaba El-Lari, Maria C. Lebre, Olaf van Tellingen, Jos H. Beijnen, and Alfred H. Schinkel

TABLE OF CONTENTS

1183 Targeted Therapy to β 3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases

Gregory C. Fox, Xinming Su, Jennifer L. Davis, Yalin Xu, Kristin A. Kwakwa, Michael H. Ross, Francesca Fontana, Jingyu Xiang, Alison K. Esser, Elizabeth Cordell, Kristen Pagliai, Ha X. Dang, Jothilingam Sivapackiam, Sheila A. Stewart, Christopher A. Maher, Suzanne J. Bakewell, James A.J. Fitzpatrick, Vijay Sharma, Samuel Achilefu, Deborah J. Veis, Gregory M. Lanza, and Katherine N. Weilbaecher

MODELS AND TECHNOLOGIES

1199 Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem Cells
Yingchao Xue, Yi Fu, Fenghong Zhao, Gege Gui, Yuguang Li, Samuel Rivero-Hinojosa, Guanshu Liu, Yunqing Li, Shuli Xia, Charles G. Eberhart, and Mingyao Ying

1210 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening


AC Li Wan, Jun Yin, John Skoko, Russell Schwartz, Mei Zhang, Philip R. LeDuc, and Carola A. Neumann

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

An X-ray crystal structure of auto-palmitoylation inhibitor VT105 bound to TEAD3. On page 986, researchers at Vivace Therapeutics report discovery and optimization of TEAD auto-palmitoylation inhibitors that selectively inhibit proliferation and tumor growth of *NF2*-deficient mesothelioma. These auto-palmitoylation inhibitors present an opportunity to treat cancers and other diseases that arise from abnormal inactivation of the Hippo signaling pathway.



Molecular Cancer Therapeutics

20 (6)

Mol Cancer Ther 2021;20:959-1219.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/20/6>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/6>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.